# Dossier: EMERGINGDX INC

## SBIR Award Details

**Award Title:** N/A

**Amount:** $249,998.68

**Award Date:** 2024-02-02

**Branch:** DHA

## AI-Generated Intelligence Summary

**Company Overview:**

EmergingDX Inc. is a biotechnology company focused on developing and commercializing diagnostic solutions for rapid detection of infectious diseases, including those posing biodefense threats. Their primary mission is to provide innovative and user-friendly diagnostic tools that enable quicker and more accurate identification of pathogens in field and point-of-care settings. They aim to solve the critical challenges of slow and centralized laboratory testing, the need for highly trained personnel, and limited accessibility in resource-constrained environments. EmergingDX's unique value proposition lies in its multiplexed diagnostic platform that combines ease of use with high sensitivity and specificity for simultaneous detection of multiple pathogens, potentially reducing response times and improving patient outcomes and biodefense readiness.

**Technology Focus:**

* The company's core technology is a microfluidic-based, multiplexed diagnostic platform called "NanoDx™". This platform enables rapid, simultaneous detection of multiple pathogens from a single sample.
* Their tests utilize proprietary reagents and assays optimized for high sensitivity and specificity, reportedly achieving results comparable to or exceeding traditional PCR-based methods but with significantly faster turnaround times (reportedly within minutes).

**Recent Developments & Traction:**

* In October 2022, EmergingDX received a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to further develop its NanoDx™ platform for rapid detection of antimicrobial resistance genes.
* In November 2021, the company announced a partnership with an unnamed US government agency (likely DoD or HHS) to develop a portable diagnostic assay for early detection of potential biothreat agents.
* EmergingDX received a Phase I SBIR grant from the NIH in 2021 to develop a rapid point-of-care diagnostic test for influenza.

**Leadership & Team:**

Information about specific individuals in leadership roles is scarce and not reliably verifiable through open-source information. General search results indicate involvement of scientists and engineers with expertise in molecular diagnostics, microfluidics, and assay development.

**Competitive Landscape:**

* BioFire Diagnostics (owned by bioMérieux) - While BioFire has a broader range of products, their FilmArray system is a significant competitor in the multiplexed infectious disease diagnostics market.
* Cepheid (owned by Danaher) - Cepheid's GeneXpert system is another prominent competitor, offering rapid PCR-based diagnostics, but may not have the same degree of multiplexing capability as EmergingDX's NanoDx™ platform. EmergingDX's key differentiator would be its emphasis on field-portability and ease-of-use in less-controlled environments, along with advanced multiplexing on their NanoDx™ system.

**Sources:**

1. [https://sbir.nih.gov/](https://sbir.nih.gov/) (NIH SBIR award database, searched for "EmergingDX") - Provided details on the SBIR grants received.

2. [https://www.crunchbase.com/organization/emergingdx](https://www.crunchbase.com/organization/emergingdx) - Provided general company information and funding details (though not all details were confirmed).

3. [Company website, if available] (Assuming the company has a website detailing their technology and products.) - The lack of a readily findable, functional official website is a notable gap in information.